What is Pheast?
Founded in 2020, Pheast Therapeutics operates at the intersection of immunology and oncology. The company is dedicated to the discovery and development of novel checkpoint therapies designed to overcome the immunosuppressive tumor microenvironment. By focusing on innate immune pathways, Pheast aims to unlock new therapeutic modalities that offer superior efficacy compared to traditional treatment protocols. Their market position is bolstered by a robust intellectual property portfolio and a clear focus on high-unmet-need cancer indications, making them a key player in the evolving landscape of biotechnology innovation.
How much funding has Pheast raised?
Pheast has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2022): $76M with participation from Risk and Return, Catalio Capital Management, ARCH Venture Partners, and Alexandria Venture Investments
Key Investors in Pheast
ARCH Venture Partners
A premier early-stage venture capital firm that specializes in co-founding and scaling life sciences and advanced technology companies by commercializing innovations from academic and research institutions.
Catalio Capital Management
A New York-based investment firm focused on breakthrough biomedical technology, leveraging a deep network of venture partners to support healthcare companies across all stages of development.
Risk and Return
A venture capital firm dedicated to investing in companies that enhance national resilience and stability, supporting innovative solutions that address critical societal and security risks.
What's next for Pheast?
With the successful closure of this major strategic investment, Pheast Therapeutics is poised to expand its research and development capabilities significantly. The company's roadmap includes the acceleration of its lead programs into clinical trials and the expansion of its internal talent pool to support complex drug discovery efforts. As the firm continues to refine its checkpoint modulation platform, the focus will shift toward establishing strategic partnerships and securing long-term clinical data that validates its unique mechanism of action. Investors and industry observers alike are monitoring Pheast as it seeks to redefine the standard of care in cancer immunotherapy through its innovative, science-led approach.
See full Pheast company page
